We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gold Nanoparticles Coated with Antibodies Bind to Flu Viruses

By LabMedica International staff writers
Posted on 21 Sep 2011
Gold nanoparticles coated with antibodies bind to specific strains of flu viruses. More...
Influenza can be detected in minutes by measuring how the particles scatter laser light.

The gold nanoparticle-antibody complex aggregates with any virus present in a sample, and a commercially available device measures the intensity with which the solution scatters light. The clustering of the virus with the gold nanoparticles causes the scattered light to fluctuate in a predictable and measurable pattern.

“We’ve known for a long time that you can use antibodies to capture viruses and that nanoparticles have different traits based on their size,” said Professor Ralph Tripp, Georgia research alliance eminent scholar in vaccine development in the University of Georgia (UGA) College of Veterinary Medicine (Athens, GA, USA). “What we’ve done is combine the two to create a diagnostic test that is rapid and highly sensitive.”

“This test offers tremendous advantages for influenza, but we really don’t want to stop there,” Prof. Tripp said. “Theoretically, all we have to do is exchange our anti-influenza antibody out with an antibody for another pathogen that may be of interest, and we can do the same test for any number of infectious agents.”

The current standard for definitively diagnosing flu is the polymerase chain reaction (PCR). PCR can only be done in highly specialized labs and it requires that specially trained personnel incubate the sample for three days, extract the DNA, and then amplify it many times. The entire process, from sample collection to result, takes about a week and is too costly for routine testing.

A rapid test known as the lateral flow assay is cost effective and can be used at the point-of-care, but it cannot identify the specific viral strain. It also misses up to 50% of infections and is especially error-prone when small quantities of virus are present.

By overcoming the weaknesses of existing diagnostic tests, the UGA scientists hope to enable more timely diagnoses that can help halt the spread of flu by accurately identifying infections and allowing physicians to begin treatment early, when antiviral drugs, such as Tamiflu, are most effective.

The new detection method using antibodies coated with gold nanoparticles developed at the University of Georgia was described in the August 2011 edition of the journal Analyst.

Related Links:

University of Georgia College of Veterinary Medicine



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.